Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Cash & Equivalents (2021 - 2025)

PAVmed has reported Cash & Equivalents over the past 5 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $1.5 million for Q4 2025, up 26.58% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 26.58% YoY), and the annual figure for FY2025 was $1.5 million, up 26.58%.
  • Cash & Equivalents for Q4 2025 was $1.5 million at PAVmed, down from $3.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PAVM hit a ceiling of $77.3 million in Q4 2021 and a floor of $1.2 million in Q4 2024.
  • Median Cash & Equivalents over the past 5 years was $31.8 million (2023), compared with a mean of $32.3 million.
  • Biggest five-year swings in Cash & Equivalents: soared 52.07% in 2022 and later tumbled 93.97% in 2024.
  • PAVmed's Cash & Equivalents stood at $77.3 million in 2021, then tumbled by 48.56% to $39.7 million in 2022, then tumbled by 50.59% to $19.6 million in 2023, then tumbled by 93.97% to $1.2 million in 2024, then increased by 26.58% to $1.5 million in 2025.
  • The last three reported values for Cash & Equivalents were $1.5 million (Q4 2025), $3.1 million (Q3 2025), and $4.0 million (Q2 2025) per Business Quant data.